News | Stents Bioresorbable | October 12, 2018

Reva Presents Key Data on its Bioresorbable Stents at TCT 2018

A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES. #TCT #TCT2018 #TCT18 #BRS #bioresorbablestents #bioresorbablescaffolds

A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES. 

OCT images showing neointimal strut coverage on the Reva Fantom bioresorbable stent from a FANTOM II trial case sample. It shows matched OCT images at baseline, six months and 24 months. #TCT #TCT2018 #TCT18 #BRS #bioresorbablestents #bioresorbablescaffolds

OCT images showing neointimal strut coverage on the Reva Fantom bioresorbable stent from a FANTOM II trial case sample. It shows matched OCT images at baseline, six months and 24 months. 


October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom bioresorbable scaffold (BRS) at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference. The presentations included new procedural data from an indication expansion study in patients experiencing acute heart attacks as well as positive clinical and imaging results of the Fantom BRS through two years.

Watch a VIDEO showing the Fantom stent in "Editor’s Choice of the Most Innovative New Technology at TCT 2018."

 

FANTOM STEMI Procedural Results

New data from the FANTOM STEMI pilot study showed procedural success and clinical utility of the Fantom bioresorbable scaffold in a series of nine patients with acute heart attacks called ST-segment elevated myocardial infarction (STEMI). Patients experiencing a STEMI are a new patient population for Fantom. While these patients have a higher risk of complications than stable patients, the characteristics of their arterial blockages are typically well suited to BRS. The data were presented by Dr. Lukasz Koltowski from the Medical University of Warsaw in Warsaw, Poland.

“The first priority when treating heart attack patients is removing the arterial blockage to restore blood flow to the heart,” said Koltowski. “The data presented today demonstrate that Fantom, which is X-ray visible and easy to use, works effectively during these emergency procedures. Many heart attack patients are young with single blockages in their arteries, and the Fantom bioresorbable scaffold creates an opportunity for recovery without the risk of a permanent metal drug-eluting stent.”

FANTOM II Clinical Results

Two-year clinical results from the FANTOM II study were presented by Yuichi Saito, M.D., from the Yale University School of Medicine in New Haven, Conn. The data demonstrated safety and efficacy of Fantom at two years with the following outcomes:
   • Low 5 percent rate of major adverse cardiac events (MACE)
   • A single very late scaffold thrombosis event for a rate of 0.4 percent

FANTOM II Imaging Results

Two-year optical coherence tomography (OCT) imaging results from the FANTOM II study were presented by Dr. Neils Holm from the Aarhus University Hospital in Aarhus, Denmark. The data showed an excellent healing profile for Fantom with sustained vessel lumen patency and no evidence of chronic scaffold recoil through two years.

FANTOM Clinical Review

Dr. Ulf Landmesser, professor of cardiology at Charité Universitätsmedizin Berlin, Germany  delivered a comprehensive presentation of the Fantom BRS program. In addition to reviewing available clinical data, Landmesser provided an update on the Fantom Post Market Trial which is currently enrolling in Europe to evaluate
the safety of Fantom in routine clinical practice. The presentation materials delivered at the conference are available in the investor relations section of Reva’s website at www.ir.revamedical.com.

About Fantom and Fantom Encore

Fantom and Fantom Encore are sirolimus-eluting bioresorbable scaffolds developed as alternatives to metallic stents for the treatment of coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process and then disappear (or resorb) from the body over a period of time. This resorption is intended to allow the return of natural function of the artery and reduce the risk of adverse events associated with a permanent metallic drug-eluting stent. Fantom and Fantom Encore are the only coronary bioresorbable scaffolds made from Tyrocore, Reva’s proprietary tyrosine-derived polymer designed specifically for vascular scaffold applications. Tyrocore is inherently radiopaque, making Fantom and Fantom Encore visible under X-ray fluoroscopy. Fantom and Fantom Encore are designed with thin struts while maintaining strength and with distinct ease-of-use features such as X-ray visibility and expansion with one continuous inflation.

For more information: www.revamedical.com

Related Content

News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
News | Cardiovascular Clinical Studies

January 27, 2021 — A New York Institute of Technology research team has secured a five-year $1.8 million grant from the ...

Home January 27, 2021
Home
News | Cardiovascular Clinical Studies

July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to ...

Home July 22, 2020
Home
News | Cardiovascular Clinical Studies

July 1, 2020 — Carag AG announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption ...

Home July 01, 2020
Home
News | Cardiovascular Clinical Studies

January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special ...

Home January 20, 2020
Home
News | Cardiovascular Clinical Studies

Environmental and lifestyle issues were popular this year, with pick up from both European Society of Cardiology (ESC) ...

Home December 23, 2019
Home
News | Cardiovascular Clinical Studies

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

Home November 26, 2019
Home
News | Cardiovascular Clinical Studies

July 10, 2019 — The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During ...

Home July 10, 2019
Home
News | Cardiovascular Clinical Studies

July 3, 2019 — The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to ...

Home July 03, 2019
Home
News | Cardiovascular Clinical Studies

November 19, 2018 — The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent ...

Home November 19, 2018
Home
Subscribe Now